Commercial Credit Report for MALAYSIAN GENOMICS RESOURCE CENTRE BHD

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for MALAYSIAN GENOMICS RESOURCE CENTRE BHD is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	MALAYSIAN GENOMICS RESOURCE CENTRE BHD
8F Jalan Teknologi 3/6, Taman Sains Sela
Phone: +60 378900015p:+60 378900015	PETALING JAYA, 47810 Malaysia	Ticker: MGRCMGRC

Business Summary

Malaysian Genomics Resource Centre Berhad is a Malaysia-based company, which is engaged in providing personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. Its services include Genome Sequencing Services, Genome Analysis Services, Genetic Screening Services and Cancer Immunotherapy. Its whole genome sequencing (WGS) is carried out to obtain the sequence of the entire genome from any eukaryotic or prokaryotic organism. This includes plant, animal, microbial, and human genomes. It offers both de novo sequencing and resequencing as part of its WGS service. Its Genome analysis includes services, such as bioinformatics, trait analysis, and trio sequencing. Its Genetic screening includes Dtect, which offers a range of test panels designed to screen for genetic markers in an individual’s deoxyribonucleic acid (DNA). Its Cancer Immunotherapy includes chimeric antigen receptor (CAR) T-Cell immunotherapy.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8071	Medical laboratories
8731	Commercial physical and biological research
6719	Offices of holding companies, not elsewhere classified

Officers and Directors

Title	Name	Age	Title Date	Start Date
Executive Chairman of the Board	Noor AzriBin Dato' Sri Noor A	25	5/24/2023	12/27/2021
Chief Operating Officer, Executive Director	Muhammad BadriBin Hussin	50	3/4/2024	10/20/2023
Company Secretary	Lai YeeNg		12/27/2021	12/27/2021
5 additional Officers and Directors records available in full report.

General Information

Number of Employees:	19	(As of 3/31/2010)
Outstanding Shares:	137,210,480	(As of 12/31/2023)
Shareholders:	358
Stock Exchange:	KUL
Fax Number:	+60 361503232

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN